Introduction: Painful bladder syndrome or Interstitial cystitis (IC) is characterized by an unpleasant sensation (pain, pressure, and discomfort) perceived to be related to the urinary bladder and presented as urgency, frequency, nocturia, dysuria of more than 6 weeks duration, in the absence of infection or other identifiable causes. This prospective study done in Patients with symptoms of IC to assess the immediate and sustained relief after a weekly instillation for three weeks of treatment with intravesical alkalinized lidocaine and heparin. by Pelvic pain and Urgency/Frequency Valid scale (PUF)

Method: All included patient were assessed and the PUF score is calculated by the questionarre. With all aseptic precaution, solution of 40,000 U heparin +10mL, 2% Lidocaine and 10mL, 8.4% sodium bicarbonate was administered intravesically in patients and kept  for half an hour then patient is allowed to urinate.  the response to treatment was  followed  after one week and PUF score is calculated and same is repeated for 3 consecutive weeks . The percentage of improvement is calculated by the change in PUF score.

Observation: Total 20 patient (M;F -9:11) with mean PUF score is 23.70 shown significant decrease to 4.85(p= <0.001)  after first instillation.  After every instillation, there is constant decrease in PUF score.

Conclusion: It can be concluded that this intravesical therapy has greater symptom relief of painful bladder syndrome who were failing medical therapy by antimuscuranic and alpha blocker for long time.

Keywords: Interstitial cystitis(IC); intravesical; alkalinized lidocaine; heparin.

1. Hannchongkuo current the urapetic advances in chronic interstitial cystitis. tzu chi med j 2006;18:167-174
2. Satpathy Hemant K, Taylor Richert. Interstitial Cystitis J Obstet Gynecol India Vol. 58, No. 1 : January/February 2008 pg 24-31
3. Parsons CL: Successful down regulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005; 65:45-48.
4. Parsons CL, Parsons JK. Interstitial cystitis. In: Raz S, ed. Female urology. 2nd ed. Philadelphia: Saunders,1996: Chapter 15.
5. Dinis et al. bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. International Journal of Women’s Health 2015:7 735–744
6. Lee WY, Savage JR, Zhang J, Jia W, Oottamasathien S, Prestwich GD. Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan. PLoS One. 2013;8 (10):e77854.)
7. Nickel JC, Barkin J, Forrest J, et al: Randomized, double blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65:654-658.
8. Raymond Rackley, Interstitial Cystitis: Preventing Flares and Producing Clinical Remissions for IC Patients. https://my.clevelandclinic.org/ccf/media/files/Urology/Transcript_IC.pdf

Dr Deepti B. Sharma

Department of Surgery, NSCB Medical College, Jabalpur MP India